Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 25 results for gefitinib

  1. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)

    Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    28 July 2010
    View recommendations

    Sections for TA192

  2. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

    Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA374

  3. Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)

    Evidence-based recommendations on erlotinib (Tarceva) for treating EGFR-TK-positive non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    27 June 2012
    View recommendations

    Sections for TA258

  4. Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)

    Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-positive locally advanced or metastatic non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    23 April 2014
    View recommendations

    Sections for TA310

  5. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

    Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    14 August 2019
    View recommendations

    Sections for TA595

  6. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    14 October 2020

    Sections for TA654

  7. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

    In development [GID-TA11279] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  8. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

    In development [GID-TA11408] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development [GID-TA11023] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  10. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic

    Diagnostics guidance
    Published
    14 August 2013
    View recommendations

    Sections for DG9

  11. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

    Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA347

  12. NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine kinase inhibitors (afatinib, erlotinib and gefitinib) in EGFR mutation-positive locally advanced or metastatic NSCLC.

    effectiveness of the tyrosine kinase inhibitors (afatinib, erlotinib and gefitinib) in EGFR mutation-positive locally advanced or...

    Research recommendation
    Published
    9 June 2015

  13. Treatments for non-small-cell lung cancer [ID6234]

    In development [GID-TA11289] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)

    Evidence-based recommendations on erlotinib (Tarceva) for the maintenance treatment of non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    29 June 2011
    View recommendations

    Sections for TA227

  15. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    13 May 2020
    View recommendations

    Sections for TA628